PRPS1L1 Antibody

What is PRPS1L1 and why is it important in scientific research?

PRPS1L1 (phosphoribosyl pyrophosphate synthetase 1-like 1) is an enzyme that catalyzes the synthesis of phosphoribosyl pyrophosphate (PRPP), an essential substrate in nucleotide biosynthesis. It is also known as PRPS3 or PRPSL . Unlike its homologs PRPS1 and PRPS2 which are ubiquitously expressed, PRPS1L1 expression is largely restricted to the testis, making it an interesting target for tissue-specific studies .

The protein is encoded by an intronless gene and is highly homologous to the two subunits of phosphoribosylpyrophosphate synthetase . Research interest in PRPS1L1 has increased due to potential links to certain pathological conditions, including rheumatoid arthritis . Additionally, related proteins in the PRPS family have been implicated in nucleotide biosynthesis and purine metabolism disorders .

What types of PRPS1L1 antibodies are available for research applications?

Research-grade PRPS1L1 antibodies are available in several formats, characterized by different properties as summarized in the table below:

These antibodies provide researchers with options for different experimental approaches, with varying specificities for PRPS1L1 alone or cross-reactivity with related family members PRPS1 and PRPS2 .

How specific are antibodies targeting PRPS1L1 versus related family members PRPS1 and PRPS2?

Specificity varies significantly between different PRPS1L1 antibodies. Some antibodies are designed to target unique epitopes of PRPS1L1, while others recognize conserved regions across multiple PRPS family members.

For experiments requiring specific detection of PRPS1L1 without cross-reactivity to PRPS1 or PRPS2, researchers should select antibodies raised against unique regions of PRPS1L1, such as those targeting the N-terminal region (AA 77-106) . These antibodies undergo peptide affinity purification to enhance specificity.

Conversely, for experiments aimed at studying common functions across the PRPS family, antibodies that recognize multiple family members (PRPS1/2/PRPS1L1) are available . These antibodies target conserved epitopes and can be valuable for comparative studies across different tissues, as PRPS1 and PRPS2 are ubiquitously expressed while PRPS1L1 is testis-specific.

Cross-reactivity should be empirically validated when absolute specificity is critical, particularly in tissues where multiple PRPS family members may be co-expressed.

What are the optimal protocols for Western blot detection of PRPS1L1?

Western blot protocols for PRPS1L1 detection require careful optimization. Based on the literature and product specifications, the following methodology is recommended:

Sample Preparation:

• Prepare cell or tissue lysates in RIPA buffer (e.g., Solarbio, #R0020)

• Determine protein concentration using a BCA Protein Assay kit

• Load 30-40 μg of total protein per lane

Electrophoresis and Transfer:

• Separate proteins using 10% SDS-PAGE

• Transfer to PVDF membranes (e.g., Millipore, #IPVH00010)

Antibody Incubation:

• Block membrane with appropriate blocking buffer (typically 5% non-fat milk or BSA)

• Incubate with primary anti-PRPS1L1 antibody at optimal dilution:

  • For monoclonal antibodies (clone 5E10): 1-5 μg/mL

  • For polyclonal antibodies: 1:500-1:2000 dilution

• Incubate overnight at 4°C

• Wash with TBST buffer

• Incubate with appropriate HRP-conjugated secondary antibody:

  • Anti-rabbit IgG (for rabbit polyclonal antibodies)

  • Anti-mouse IgG (for mouse monoclonal antibodies)

• Develop using ECL chemiluminescence reagent

Expected Results:

• PRPS1L1 protein has a predicted molecular weight of approximately 35 kDa

• Validated in multiple cell lines including HeLa, NIH/3T3, Raw 264.7, and PC-12

For researchers encountering weak signals, optimizing lysate preparation with phosphatase inhibitors may improve detection, particularly if phosphorylation states affect epitope recognition.

How should immunohistochemistry protocols be optimized for PRPS1L1 detection in tissue samples?

For immunohistochemical detection of PRPS1L1 in tissue samples, the following protocol can be implemented:

Tissue Preparation:

• Fix tissues in 10% neutral buffered formalin

• Embed in paraffin and section at 4-6 μm thickness

• Deparaffinize and rehydrate sections through graded alcohols

Antigen Retrieval:

• Perform heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) for 20 minutes

• Allow slides to cool to room temperature

Antibody Incubation:

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Apply protein block to reduce non-specific binding

• Incubate with primary anti-PRPS1L1 antibody:

  • For polyclonal antibodies: 1:25-1:100 dilution

• Incubate overnight at 4°C

• Apply appropriate HRP-conjugated secondary antibody

• Develop with DAB substrate and counterstain with hematoxylin

Validation and Controls:

• Include positive control tissues (testis tissue is recommended as PRPS1L1 is highly expressed there)

• Include negative controls (primary antibody omitted)

• Consider dual staining with cell-type specific markers if studying co-localization

Researchers should note that PRPS1L1 subcellular localization is typically in the extracellular region or secreted, extracellular exosomes, protein complexes, and ribose phosphate diphosphokinase complexes , which may influence staining patterns observed.

What approaches should be used to validate the specificity of PRPS1L1 antibody staining?

Validating antibody specificity is critical for reliable PRPS1L1 detection. Recommended approaches include:

1. Multiple Antibody Validation:

• Compare staining patterns using antibodies targeting different epitopes of PRPS1L1

• Consistent staining patterns across different antibodies increases confidence in specificity

2. Genetic Manipulation Approaches:

• Knockdown PRPS1L1 using siRNA or shRNA

• Overexpress PRPS1L1 in cell lines with low endogenous expression

• Compare antibody reactivity in these modified versus control cells

3. Peptide Competition Assays:

• Pre-incubate antibody with excess immunizing peptide before application

• Specific staining should be blocked by the peptide

4. Tissue Distribution Analysis:

• Verify high expression in testis compared to other tissues

• Discrepancies from the expected tissue distribution pattern may indicate non-specific binding

5. Western Blot Correlation:

• Confirm that protein detected by Western blot matches the predicted molecular weight (35 kDa)

• Compare with immunohistochemistry or immunofluorescence results from the same samples

Researchers should be particularly cautious when interpreting results in cells or tissues where multiple PRPS family members are expressed, as cross-reactivity could lead to false interpretations.

How can PRPS1L1 antibodies be applied to investigate its role in cancer progression?

Recent research has implicated PRPS family proteins in cancer progression, particularly through their role in nucleotide biosynthesis. Methodological approaches for investigating PRPS1L1 in cancer include:

Expression Analysis in Cancer Tissues:

• Use PRPS1L1-specific antibodies for immunohistochemical staining of cancer tissue microarrays

• Compare expression levels between tumor and adjacent normal tissues

• Correlate expression with clinical parameters and patient outcomes

Functional Studies:

• Manipulate PRPS1L1 expression in cancer cell lines using:

  • Overexpression vectors for gain-of-function studies

  • siRNA/shRNA for loss-of-function studies

• Assess effects on:

  • Cell proliferation (using assays such as MTT, BrdU, or colony formation)

  • Cell cycle progression (using flow cytometry with PI staining)

  • Expression of cell cycle regulators (cyclin E1, CDK2, P16)

Mechanistic Investigations:

• Examine the relationship between PRPS1L1 and transcription factors:

  • For example, NRF2 has been shown to regulate PRPS1 in melanoma cells

  • Use chromatin immunoprecipitation (ChIP) to identify direct regulatory interactions

• Assess impact on downstream pathways:

  • Nucleotide synthesis pathways

  • Cell cycle regulatory networks

  • Metastasis-related proteins (MMPs, EMT markers)

Research has demonstrated that PRPS1 upregulation promotes melanoma progression by enhancing cell proliferation and influencing cell cycle regulators . Similar approaches can be applied to investigate PRPS1L1's potential roles in other cancer types.

What are the best approaches for multiplexing PRPS1L1 antibodies with other markers in co-localization studies?

For advanced co-localization studies involving PRPS1L1, researchers should consider the following multiplexing approaches:

Immunofluorescence Multiplexing:

• Select antibodies raised in different host species (e.g., rabbit anti-PRPS1L1 with mouse anti-marker of interest)

• Use fluorophore-conjugated secondary antibodies with distinct emission spectra

• Include appropriate controls:

  • Single antibody staining controls to verify specificity

  • Secondary-only controls to assess background

  • Absorption controls when spectral overlap is a concern

Sequential Immunostaining:
For situations where primary antibodies are from the same host species:

• Apply the first primary antibody

• Detect with a directly conjugated secondary antibody

• Block remaining free binding sites

• Apply the second primary antibody

• Detect with a differently conjugated secondary antibody

Confocal Microscopy Optimization:

• Set precise acquisition parameters to minimize bleed-through

• Use sequential scanning when fluorophores have closely overlapping spectra

• Apply appropriate digital post-processing algorithms for co-localization analysis

Validated Co-localization Markers:
Based on PRPS1L1's reported subcellular localization (protein complexes, ribose phosphate diphosphokinase complexes, extracellular regions) , consider co-staining with:

• Markers of nucleotide synthesis pathways

• Exosomal markers (for extracellular vesicle studies)

• Nuclear markers to distinguish nuclear vs. cytoplasmic distribution

When performing multi-color immunofluorescence, use AbBy Fluor® 488-conjugated anti-PRPS1L1 antibodies for direct detection to simplify multiplexing protocols .

How can researchers troubleshoot inconsistent results when using PRPS1L1 antibodies in different experimental systems?

Inconsistent results with PRPS1L1 antibodies across different experimental systems can arise from multiple factors. The following troubleshooting framework can help identify and resolve these issues:

1. Antibody-Related Factors:

• Epitope accessibility: Different fixation methods may mask epitopes

  • Solution: Test multiple fixation protocols (PFA, methanol, acetone)

• Antibody degradation: Repeated freeze-thaw cycles can reduce activity

  • Solution: Aliquot antibodies upon receipt and store at recommended temperature (-20°C for most)

• Lot-to-lot variation: Different production batches may have varying affinities

  • Solution: Validate each new lot against previously validated lots

2. Sample Preparation Issues:

• Protein degradation: PRPS1L1 may be susceptible to proteolysis

  • Solution: Use fresh samples and include protease inhibitors in all buffers

• Post-translational modifications: These may affect epitope recognition

  • Solution: Compare detection in samples treated with phosphatases or other modifying enzymes

3. Cross-Reactivity Concerns:

• Expression levels of related proteins: PRPS1 and PRPS2 are more widely expressed than PRPS1L1

  • Solution: Use antibodies targeting unique regions of PRPS1L1 or validate with knockout controls

• Non-specific binding: May occur in certain tissues or cell types

  • Solution: Optimize blocking conditions and increase washing stringency

4. Experimental System Differences:

• Species variations: Although many antibodies cross-react with human, mouse, and rat PRPS1L1 , sequence differences may affect binding

  • Solution: Verify antibody compatibility with the species being studied

• Cell/tissue-specific factors: Expression of PRPS1L1 varies across tissues, with highest expression in testis

  • Solution: Use appropriate positive controls (testis tissue/extracts)

5. Methodological Optimization:

• Application-specific requirements: Different applications (WB, IHC, IF) may require different antibody concentrations

  • Solution: Titrate antibody for each application using:

    • Western blot: 1:500-1:2000 or 1-5 μg/mL

    • IHC: 1:25-1:100

    • IF: Approximately 1:200

When systematic troubleshooting fails to resolve inconsistencies, consider using alternative detection methods or multiple antibodies targeting different epitopes to validate findings.

How can PRPS1L1 antibodies be utilized in studies of nucleotide metabolism disorders?

PRPS family proteins are critical in nucleotide metabolism, and mutations in PRPS1 are associated with several disorders. While PRPS1L1's role is less characterized, antibodies can be valuable tools for comparative studies:

Disease Model Analysis:

• Use PRPS1L1 antibodies alongside PRPS1/PRPS2 antibodies to compare expression patterns in:

  • PRPS1 superactivity disorders (characterized by gout and overproduction of purine nucleotides)

  • ARTS syndrome

  • Charcot-Marie-Tooth disease X-linked recessive type 5 (CMTX5)

• Examine potential compensatory changes in PRPS1L1 expression when PRPS1 is mutated

Functional Complementation Studies:

• In cell models with PRPS1 deficiency, assess whether PRPS1L1 overexpression can rescue phenotypes

• Use antibodies to confirm expression levels and localization patterns of the overexpressed protein

PRPP Synthesis Pathway Investigations:

• Employ PRPS1L1 antibodies in immunoprecipitation experiments to identify:

  • Interaction partners specific to PRPS1L1 versus other family members

  • Potential regulatory proteins that may modulate PRPS1L1 activity differently from PRPS1/PRPS2

Testis-Specific Metabolism Research:

• Given PRPS1L1's testis-specific expression , investigate its role in:

  • Spermatogenesis

  • Testicular metabolism

  • Male fertility

• Use tissue-specific knockout models followed by antibody-based verification of PRPS1L1 depletion

These approaches can help elucidate whether PRPS1L1 has specialized functions in testicular nucleotide metabolism that differ from the more ubiquitously expressed PRPS1 and PRPS2.

What are the considerations for using PRPS1L1 antibodies in studies of potential therapeutic targeting of the PRPS pathway?

The PRPS pathway represents a potential therapeutic target in various conditions, including cancer and metabolic disorders. Researchers investigating this avenue should consider:

Target Validation Studies:

• Use PRPS1L1 antibodies to assess expression levels across:

  • Normal tissues (focusing on testis as the primary site of expression)

  • Pathological tissues (particularly in conditions with dysregulated nucleotide metabolism)

• Correlate expression with disease progression, prognosis, or treatment response

Inhibitor Development and Evaluation:

• For compounds designed to inhibit PRPS activity:

  • Use antibodies in pull-down assays to confirm direct binding to PRPS1L1

  • Employ immunoblotting to assess effects on total protein levels and potential degradation

  • Apply immunofluorescence to monitor changes in subcellular localization following treatment

On-Target vs. Off-Target Effects Assessment:

• When evaluating PRPS-targeted therapies, use PRPS1L1 antibodies alongside PRPS1/PRPS2 antibodies to:

  • Determine selectivity profiles of inhibitors

  • Assess potential compensatory changes in expression among family members

  • Identify tissue-specific effects (particularly important given PRPS1L1's restricted expression pattern)

Biomarker Development:

• Investigate PRPS1L1 as a potential biomarker by:

  • Developing quantitative immunoassays using validated antibodies

  • Correlating protein levels with clinical parameters

  • Determining whether antibody-detected levels can predict treatment response

Therapeutic Antibody Considerations:

• For researchers exploring PRPS1L1 as a direct therapeutic target:

  • Evaluate antibodies for their ability to modulate enzyme activity

  • Assess internalization of antibody-PRPS1L1 complexes

  • Explore potential for antibody-drug conjugates targeting PRPS1L1-expressing cells

The testis-specific expression of PRPS1L1 may offer advantages for targeted therapies by potentially limiting off-target effects in other tissues, though this would primarily be relevant for testicular pathologies.

How can advanced imaging techniques enhance the utility of PRPS1L1 antibodies in research?

Advanced imaging methodologies can significantly expand the research applications of PRPS1L1 antibodies beyond traditional techniques. Researchers should consider:

Super-Resolution Microscopy:

• Apply techniques such as STORM, PALM, or SIM using fluorophore-conjugated PRPS1L1 antibodies to:

  • Resolve PRPS1L1 distribution within subcellular structures at nanometer resolution

  • Visualize potential protein complexes involving PRPS1L1

  • Detect changes in molecular organization under different experimental conditions

• Recommended antibody modifications:

  • Use directly conjugated (e.g., AbBy Fluor® 488) anti-PRPS1L1 antibodies

  • For unconjugated primary antibodies, select secondary antibodies optimized for super-resolution imaging

Live-Cell Imaging:

• For monitoring dynamic processes:

  • Combine anti-PRPS1L1 antibody fragments (Fab) with cell-penetrating peptides

  • Use fluorescently tagged nanobodies if available

• Applications include:

  • Tracking changes in PRPS1L1 localization during cell cycle progression

  • Monitoring responses to metabolic perturbations in real-time

Correlative Light and Electron Microscopy (CLEM):

• Use immunogold-labeled PRPS1L1 antibodies to:

  • Precisely localize PRPS1L1 within cellular ultrastructure

  • Identify association with specific organelles or membrane domains

• Implementation considerations:

  • Optimize fixation and embedding protocols to preserve both antigenicity and ultrastructure

  • Use antibodies validated for immunogold labeling

Proximity Ligation Assay (PLA):

• Combine PRPS1L1 antibodies with antibodies against potential interaction partners to:

  • Detect protein-protein interactions in situ with single-molecule sensitivity

  • Quantify changes in interaction frequency under different conditions

• Technical considerations:

  • Use antibodies from different host species or directly conjugated oligo-linked antibodies

  • Include appropriate controls to verify specificity of detected interactions

Expansion Microscopy:

• Apply PRPS1L1 antibodies in expanded samples to:

  • Achieve super-resolution imaging on standard microscopes

  • Improve visualization of PRPS1L1 in dense structures

These advanced imaging approaches require careful optimization of antibody concentration, incubation conditions, and signal amplification methods to achieve optimal results while maintaining specificity.

What is the optimal strategy for detecting low-abundance PRPS1L1 in non-testicular tissues?

PRPS1L1 is predominantly expressed in testis, making its detection in other tissues challenging. Researchers investigating low-abundance expression should consider:

Signal Amplification Methods:

• Tyramide Signal Amplification (TSA):

  • Use HRP-conjugated secondary antibodies followed by fluorescent tyramide deposition

  • Can increase sensitivity by 10-100 fold over conventional detection

• Polymer-based detection systems:

  • Employ polymers carrying multiple HRP molecules and secondary antibodies

  • Provides significant signal enhancement without increased background

Sample Enrichment Techniques:

• Subcellular fractionation:

  • Isolate cellular compartments where PRPS1L1 is expected (extracellular exosomes, protein complexes)

  • Concentrate the protein of interest prior to detection

• Immunoprecipitation:

  • Use validated anti-PRPS1L1 antibodies for pull-down

  • Analyze concentrated proteins by Western blot

Optimized Western Blot Protocol:

• Increase protein loading (up to 80-100 μg per lane, compared to standard 30-40 μg)

• Use high-sensitivity ECL substrates with longer exposure times

• Consider PVDF membranes with smaller pore sizes (0.2 μm vs. standard 0.45 μm)

• Select antibodies with proven sensitivity:

  • For Western blot: 1:500-1:1000 dilution range is recommended for maximum sensitivity

RT-qPCR Correlation:

• Complement protein detection with mRNA analysis

• Design primers specific to PRPS1L1 to distinguish from PRPS1/PRPS2

• Verify detected transcripts by sequencing to confirm specificity

Multiple Antibody Approach:

• Use antibodies targeting different epitopes:

  • N-terminal targeting antibodies (AA 77-106)

  • Central region antibodies (AA 146-243)

• Concordant results across different antibodies increase confidence in low-level detection

Researchers should be particularly cautious about cross-reactivity with the more abundant PRPS1 and PRPS2 proteins when attempting to detect low levels of PRPS1L1 in non-testicular tissues.

How can ChIP protocols be optimized when using PRPS1L1 antibodies for transcriptional regulation studies?

While PRPS1L1 itself is not a transcription factor, researchers investigating its transcriptional regulation (similar to studies of NRF2 regulation of PRPS1 ) may need to perform ChIP assays. For these studies:

Antibody Selection for ChIP:

• Choose antibodies validated for immunoprecipitation applications

• Prefer antibodies recognizing native (non-denatured) epitopes

• Verify ChIP-grade quality or test the antibody's ability to immunoprecipitate the target protein

Crosslinking Optimization:

• Standard formaldehyde crosslinking (1%) for 10 minutes at room temperature

• For potentially weak or transient interactions, consider:

  • Dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde

  • Optimized crosslinking times based on preliminary experiments

Chromatin Preparation:

• Sonication conditions should be carefully optimized to achieve fragments of 200-500 bp

• Verify fragmentation efficiency by agarose gel electrophoresis

• Pre-clear chromatin with protein A/G beads to reduce background

Immunoprecipitation Protocol:

• Use 2-5 μg of antibody per ChIP reaction

• Include appropriate controls:

  • IgG control from the same species as the primary antibody

  • Input control (typically 1-5% of starting chromatin)

  • Positive control (antibody against known transcription factor)

Analysis Strategies:

• Conventional PCR: Design primers flanking predicted binding sites

• qPCR: For quantitative analysis of enrichment

• ChIP-seq: For genome-wide binding site identification

Validation of Results:

• Reporter gene assays to confirm functional significance of identified binding sites

• Mutational analysis of binding sites

• Correlation with gene expression changes

For studies specifically examining transcription factors that regulate PRPS1L1 expression, the ChIP assay should be complemented with luciferase reporter assays similar to those used in PRPS1 regulation studies .

What considerations are important when using PRPS1L1 antibodies for flow cytometry applications?

Flow cytometry with PRPS1L1 antibodies presents unique challenges due to the protein's subcellular localization and limited expression pattern. Researchers should consider:

Cell Preparation and Fixation:

• For intracellular detection:

  • Fix cells with 4% paraformaldehyde for 15 minutes

  • Permeabilize with 0.1% Triton X-100 or commercial permeabilization buffers

• For detecting PRPS1L1 in exosomes or on cell surface:

  • Use mild fixation (0.5-1% paraformaldehyde)

  • Avoid permeabilization agents

Antibody Selection and Validation:

• Not all PRPS1L1 antibodies are validated for flow cytometry

• Verify antibody performance in:

  • Cells known to express PRPS1L1 (testicular cell lines)

  • Cells with engineered PRPS1L1 overexpression

  • Negative control cells (PRPS1L1 knockdown or non-expressing lines)

Staining Protocol Optimization:

• Antibody concentration:

  • Start with manufacturer's recommended dilution

  • Perform titration experiments to determine optimal concentration

• Incubation conditions:

  • Extended incubation (overnight at 4°C) may improve signal for low abundance targets

  • Include gentle agitation during incubation

Controls and Gating Strategy:

• Essential controls:

  • Isotype control matched to primary antibody

  • Unstained cells for autofluorescence assessment

  • FMO (Fluorescence Minus One) controls for multicolor panels

• Gating recommendations:

  • Gate on viable cells using appropriate viability dyes

  • For tissues with heterogeneous cell populations, include markers to identify specific cell types

Signal Amplification Considerations:

• For low-abundance detection:

  • Consider biotin-streptavidin amplification systems

  • Use fluorophores with higher quantum yield (e.g., PE instead of FITC)

Data Analysis Approaches:

• For quantitative studies:

  • Report median fluorescence intensity (MFI) rather than mean

  • Calculate signal-to-noise ratio relative to appropriate controls

• For expression heterogeneity:

  • Consider visualization tools for high-dimensional data (tSNE, UMAP)

  • Analyze co-expression with other markers of interest